In a report released today, Joseph Schwartz from Leerink Partners maintained a Buy rating on uniQure (QURE – Research Report), with a price target of $56.00. The company’s shares closed last Monday at $15.77, close to its 52-week low of $14.29.
According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.8% and a 27.9% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.
uniQure has an analyst consensus of Strong Buy, with a price target consensus of $57.40, a 283.2% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $53.00 price target.
The company has a one-year high of $38.80 and a one-year low of $14.29. Currently, uniQure has an average volume of 528K.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE: